Decoding cellular messengers 
to ENABLE curative treatments FOR CANCER

AI-enabled liver cancer tests

who are the patients?

High-risk populations for liver cancer

Nearly 10 million people in the United States and Europe are at high risk of developing liver cancer. This growing number of individuals is primarily comprised of patients with cirrhosis (scarring of the liver), which has various causes, such as obesity leading to metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis (B and C), and excessive alcohol consumption.

Early detection of liver cancer enables access to curative treatments such as ablation, resection, and transplants. Clinical best practice is for high risk patients to undergo biannual screening using ultrasound; however, the results are often insufficiently sensitive to detect early-stage cancers.

Mursla Bio is conducting a clinical study involving approximately 500 patients to validate a novel in vitro diagnostic (IVD) test to meet this clinical need.

learn more

WHAT DO WE ANALYSE?

Liver-derived EVs in blood

Cells within organs, including the liver, continually secrete tiny membrane-bound particles known as Extracellular Vesicles (EVs). These EVs are packed with various biological materials such as DNA, RNA, proteins, lipids, and metabolites, offering a real-time glimpse into the health of the originating cell.

Some of these EVs manage to navigate through the extracellular matrix and enter the bloodstream. Once in the circulation, they carry essential information from cell to cell, as well as between different tissues and organs.

When a blood sample is taken, it contains billions of these EVs and hundreds of thousands are derived from vital organs like the liver as explained in our 3D video.

learn more

HOW DO WE ANALYSE?

Novel liver-EV liquid biopsy platform

Mursla Bio's cutting-edge technology analyses rare, tissue-specific EVs in blood, such as those originating from the liver, with unmatched precision. This enables non-invasive tissue biopsy of a patient at any time, detecting disease biosignatures, like cancer, at onset or recurrence. 

This breakthrough is made possible by our AI-empowered biomarker discovery platform, coupled with compatible high-throughput assays for clinical use. It features a suite of proprietary and patented innovations. 

Our approach is not only specific but also extends across multiple 'omics' such as RNA, protein and glycan, in order to better approximate the phenotype of the originating cells.

learn more

OUR news

Mursla Bio enters the US market with strategic expansion

Mursla Bio launches US strategy to bring its novel liquid biopsy tests – based on extracellular vesicle technology – to patients
NEXOS

Mursla Bio presents breakthrough liquid biopsy technology for extracellular vesicles in Cell Press

Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience

Mursla Bio helps shape the standardisation of EV-based liquid biopsy for clinical use

Mursla Bio participates in a unique global initiative to standardise the clinical use of novel EV-based biomarkers for liquid biopsy

Our Partners